• Free research grade Molecular reports*.
• Molecular tumour boards discussions*.
• Access to all broad profiling data (raw and processed data) from your patients*.
• The institution will be compensated 250 euros per patient confirmed as eligible (up to 2500 euros for some progression specimen (metastatic patients eligible to IMMUcan).
• All costs for HBM shipment and analyses are covered.
• Possibility of authorship on publications (e.g. as part of a scientific collaboration).

*MTB, molecular reports and sequencing data are available only if the sequencing is performed as part of the downstream project.

• Access to high quality molecular and clinical datasets for biomarker and treatment strategy research (data sharing^*).
• Opportunities to propose innovative analysis of left-over biological material (sample and data sharing^*).
• Material and clinical data are clinical trial grade (longitudinal follow up, quality-controlled processes for data and sample collection and processing).

*Data and Sample sharing

The leftover of collected Human Biological Material are stored in a central Biobank. Data requestors interested in developing translational downstream project are invited to contact specta@eortc.org and follow the steps described here.